Johnson & Johnson (JNJ)vsProtalix Biotherapeutics Inc (PLX)
JNJ
Johnson & Johnson
$254.95
+0.20%
HEALTHCARE · Cap: $615.36B
PLX
Protalix Biotherapeutics Inc
$2.37
+2.16%
HEALTHCARE · Cap: $190.15M
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 128111% more annual revenue ($97.93B vs $76.38M). JNJ leads profitability with a 21.5% profit margin vs 20.1%. PLX trades at a lower P/E of 12.4x. PLX earns a higher WallStSmart Score of 60/100 (C+).
JNJ
Buy57
out of 100
Grade: C
PLX
Buy60
out of 100
Grade: C+
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 25 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 28.6%
Generating 3.4B in free cash flow
Strong operational efficiency at 62.6%
Revenue surging 233.7% year-over-year
Every $100 of equity generates 23 in profit
Keeps 20 of every $100 in revenue as profit
Conservative balance sheet, low leverage
Attractively priced relative to earnings
Areas to Watch
Moderate valuation
Expensive relative to growth rate
Earnings declined 1.0%
Smaller company, higher risk/reward
Weak financial health signals
Earnings declined 1.0%
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.5% and operating margin at 28.6%.
Bull Case : PLX
The strongest argument for PLX centers on Operating Margin, Revenue Growth, Return on Equity. Profitability is solid with margins at 20.1% and operating margin at 62.6%. Revenue growth of 233.7% demonstrates continued momentum.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : PLX
The primary concerns for PLX are Market Cap, Piotroski F-Score, EPS Growth.
Key Dynamics to Monitor
JNJ profiles as a mature stock while PLX is a growth play — different risk/reward profiles.
JNJ carries more volatility with a beta of 0.23 — expect wider price swings.
PLX is growing revenue faster at 233.7% — sustainability is the question.
JNJ generates stronger free cash flow (3.4B), providing more financial flexibility.
Bottom Line
PLX scores higher overall (60/100 vs 57/100), backed by strong 20.1% margins and 233.7% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Protalix Biotherapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel, Brazil, the rest of Latin America and internationally. The company is headquartered in Karmiel, Israel.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?